Menopausal Disorders is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Menopausal Disorders have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Menopausal Disorders compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Menopausal Disorders overview
Menopausal disorders encompass a range of symptoms and health issues that arise during and after menopause, a natural biological process marking the end of a woman’s reproductive years. Common menopausal symptoms include hot flashes, night sweats, mood swings, and changes in sleep patterns. Hormonal fluctuations during this transition can also lead to conditions such as vaginal atrophy, affecting the genital tissues, and osteoporosis, a loss of bone density. Additionally, menopausal women may experience challenges related to sexual health and emotional well-being. Management often involves hormone replacement therapy, lifestyle modifications, and medications to address specific symptoms and reduce long-term health risks associated with hormonal changes. Regular medical check-ups and open communication with healthcare providers play a crucial role in navigating menopausal disorders effectively.
For a complete picture of PTSR and LoA scores for drugs in Menopausal Disorders, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
